Aimed Bio에임드바이오
0009K0 · KOSDAQ · ₩0009K0 · 에임드바이오
₩18,860▼ ₩990 (4.99%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| Q2 2026 | Q1 2026 | Q4 2025 | |
|---|---|---|---|
| Revenue | ₩20B | ₩8.5B | ₩38B |
| Operating income | ₩8.5B | −₩4B | ₩26B |
| Net income | ₩11B | −₩2B | ₩35B |
| Net income to shareholders | ₩11B | −₩2B | ₩35B |
Balance sheet
| Q2 2026 | Q1 2026 | Q4 2025 | |
|---|---|---|---|
| Total assets | ₩212B | ₩200B | ₩199B |
| Current assets | ₩114B | ₩97B | ₩179B |
| Cash and equivalents | ₩30B | ₩12B | ₩106B |
| Total liabilities | ₩7.5B | ₩8B | ₩6.4B |
| Current liabilities | ₩6.6B | ₩6.8B | ₩5.7B |
| Borrowings | ₩511M | ₩130M | ₩703M |
| Total equity | ₩204B | ₩192B | ₩193B |
| Shareholders' equity | ₩204B | ₩192B | ₩193B |
Cash flow
| Q2 2026 | Q1 2026 | Q4 2025 | |
|---|---|---|---|
| Cash from operations | ₩2.2B | −₩7.1B | ₩20B |
| Capital spending | ₩516M | ₩439M | ₩85M |
| Free cash flow | ₩1.7B | −₩7.5B | ₩20B |
Consolidated where available. Amounts in won.
Also known as: Aimed Bio / 에임드바이오 / 0009K0 / KRX:0009K0
Source: KRX statistical information